News chronological

Showing 9 items before 1162119

Filters Applied:

NEWSNATIONNOW (Damita Menezes) - New therapy could stop GLP-1-related muscle loss

The therapy blocks a gene called ZFP423.

What specific side effect of GLP-1 medications is a new therapy attempting to stop?
The therapy is designed to stop GLP-1-related muscle loss.
Q&A ID e61da9cc-0d92-45e5-8874-60017b79d92b
What is the mechanism of the new therapy designed to prevent muscle loss related to GLP-1?
The therapy works by blocking a gene called ZFP423.
Q&A ID 9defb739-d206-4f1a-ab5b-90b2e997bc8f
What specific side effect of GLP-1 medications is the new ZFP423-blocking therapy designed to prevent?
The therapy is designed to stop GLP-1-related muscle loss.
Q&A ID e633c75e-28f5-4e8f-abf5-f72dbcbeec52
What is the mechanism of the new therapy being developed to address muscle loss related to GLP-1?
The therapy works by blocking a specific gene called ZFP423.
Q&A ID 5ac2ceb8-a992-4db7-8933-cd471ffc1499

YOUTUBE (NewsNation) - 'Are they okay?': Hollywood's too-thin problem and the $300K fix | The Scoop

Hollywood's GLP-1 boom has a hidden price. Host Paula Froelich talks to Lizzie Straus, co-founder and CEO of telehealth company Mino, about when weight loss crosses from healthy to dangerous and why patients are looking for "gentler" options. Then, plastic surgeon Dr. Anil Shah breaks down "Ozempic face," the surge in facelifts and fillers and what it costs to fix rapid weight loss: anywhere from $40,000 to $300,000. Disclosure: Mino sells weight-loss treatments. Paula Froelich is a patient using peptides. This video is not medical advice; talk to your doctor before starting or stopping any medication.

AMERICANALMANAC (Ken Jacobs) - Gracie McGraw says three years on Ozempic triggered her eating disorder relapse

The 29-year-old daughter of Tim McGraw and Faith Hill revealed she now considers the popular weight-loss drug "probably one of the worst things" she ever did for herself, a cautionary note as millions of Americans chase the same shortcut. Gracie McGraw took to Instagram Stories on Monday to lay out, in blunt terms, what three […] The post Gracie McGraw says three years on Ozempic triggered her eating disorder relapse appeared first on American Almanac .

The 29-year-old daughter of Tim McGraw and Faith Hill revealed she now considers the popular weight-loss drug "probably one of the worst things" she ever did for herself, a cautionary note as millions of Americans chase the same shortcut. Gracie McGraw took to Instagram Stories on Monday to lay out, in blunt terms, what three years on Ozempic cost her. She started the drug in 2022 after being diagnosed with polyendocrine metabolic ovarian syndrome, a hormonal condition, previously called PCOS, that can cause irregular periods, weight gain, and long-term risks like type 2 diabetes. The drug did what it was supposed to do. It helped manage her symptoms. It made her lose weight. And it fed a disorder she thought she had left behind. As Page…Open

STRIPES (Matthew Adams) - Marine Corps revises how to measure body fat, goes slightly slimmer than Pentagon policy | Stars and Stripes

The Marines’ waist-to-height standard for body composition shall be less than or equal to 0.52, slimmer than the Pentagon’s requirement of 0.55.

THENATIONALPULSE (Pulse Wires) - Medicare Launches New Weight Loss Drug Pipeline.

Medicare's first-of-its-kind weight-loss drug program has officially launched, giving American seniors access to GLP-1 drugs at a subsidized cost.

Medicare’s new weight-loss drug program offers affordable access to GLP-1 medication for seniors, marking a significant shift in healthcare coverage and efforts to combat obesity . PULSE POINTS WHAT HAPPENED: Medicare’s first-of-its-kind weight-loss drug program has officially launched, giving American seniors access to GLP-1 drugs at a subsidized cost. DETAIL: On Wednesday, Medicare & Medicaid Services launched a new program allowing Americans aged 65 and older to access weight-loss drugs at a reduced cost of $50 a month, starting with an 18-month trial period. This is the first time Medicare has offered coverage for GLP-1 weight-loss drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Foundayo and Zepbound. Previously, Medicare…Open